Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$8.99 USD
+0.06 (0.67%)
Updated May 31, 2024 04:00 PM ET
After-Market: $9.01 +0.02 (0.22%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Oric Pharmaceuticals, Inc. [ORIC]
Reports for Purchase
Showing records 41 - 55 ( 55 total )
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Higher Risk for ORIC-101 + Xtandi in Prostate Cancer; Lowering PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-533 Monotherapy Phase 1 Trial Starting in 2H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging, Albeit Early, ORIC-101 Data; 1Q21 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Numerous Pre-Clinical AACR Presentations Show Pipeline Depth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
ORIC-101 Phase 1b Expansion Cohorts Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Selective EGFR/HER2 Exon 20 Insertion Inhibitor In-Licensed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
PRC2 Inhibitor In-Licensed; 2Q20 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eradicating Resistance in Cancer; Initiating at Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Oric Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Eradicating Resistance in Cancer; Initiating at Buy and $52 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R